P1-20-3 - Evaluation of the Immune Marker in Post-Auto Hsct Patient with Malignant Lymphoma

Abstract

Purpose: This research evaluated the influence of auto HSCT on the immune functions in lymphoma patients.Patients and methods: Thirty patients with relapsed lymphoma were treated by high dose chemotherapy with auto HSCT (support) at Fujita Health University Hospital between August 2007 and December 2012. Of those, 15patients were evaluated in this study. 15 patients, including twelve of 1st relapsed and three of 2nd relapsed, 34 to 75(median 56) years old, the pathological diagnosis are 12 of diffuse large B cell lymphoma, 1 of follicular lymphoma, 1 of Hodgkin's lymphoma and 1 of subcutaneous panniculitis like T-cell lymphoma. The high dose chemotherapy before auto HSCT were 7 L-PAM + TESPA and 8 LEED (L-PAM, ETP, CPA, Dex) regimen. Before and after 1, 3, 6, 9 and 12 months periods of HSCT, lymphocyte subsets (CD3, CD4, CD8, CD20 positive cell counts and CD4/8 ratio) and serum immunoglobulin(Ig)G, A, M level were examined. 1.9 to 15.8(median 4.3)x106/kg CD34 + cells were transplanted. The median CD4 + , CD8+ cell counts and CD4/8 ratio before HSCT were 262/μl, 234/μl and 1.08 respectively. Those were 181/μl, 1,404/μl, 0.15 at 1months after HSCT and 213/μl, 889/μl, 0.27 at 6 months after HSCT. CD4+ and CD8+ cells reached to 207/μl and 472/μl at 12 months after PBSCT. The median IgG level before HSCT was 939mg/dl and it changed to 623 mg/dl,669mg/dl and 788mg/dl at 1,6 and 12 months after HSCT.Conclusion: CD8+ cell increased greatly after HSCT. So, CD4/8 ratio did not reach 1.0 even at 12 months after HSCT. 12 months after HSCT, IgG recovered to 83.9% level of before HSCT. This research is considered to link to risk prediction for infectious complications after HSCT. Further research is required in order to evaluate the association between the immune system and complications after HSCT.